## Takashi Matsushita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3169712/publications.pdf

Version: 2024-02-01

173 papers 10,213 citations

41344 49 h-index 97 g-index

177 all docs

177 docs citations

times ranked

177

10554 citing authors

#	Article	IF	CITATIONS
1	Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood, 2011, 117, 530-541.	1.4	969
2	Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. Journal of Clinical Investigation, 2008, 118, 3420-30.	8.2	762
3	Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature, 2012, 491, 264-268.	27.8	568
4	The Development and Function of Regulatory B Cells Expressing IL-10 (B10 Cells) Requires Antigen Receptor Diversity and TLR Signals. Journal of Immunology, 2009, 182, 7459-7472.	0.8	443
5	B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Annals of the New York Academy of Sciences, 2010, 1183, 38-57.	3.8	394
6	Regulatory B Cells (B10 Cells) and Regulatory T Cells Have Independent Roles in Controlling Experimental Autoimmune Encephalomyelitis Initiation and Late-Phase Immunopathogenesis. Journal of Immunology, 2010, 185, 2240-2252.	0.8	341
7	Bâ€lymphocyte contributions to human autoimmune disease. Immunological Reviews, 2008, 223, 284-299.	6.0	306
8	Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 2013, 8, e60442.	2.5	306
9	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis. Archives of Dermatology, 2011, 147, 391.	1.4	293
10	Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology, 2007, 46, 25-28.	1.9	277
11	Myositisâ€specific anti‶55/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis and Rheumatism, 2012, 64, 513-522.	6.7	245
12	Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis and Rheumatism, 2006, 54, 192-201.	6.7	242
13	Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Annals of the Rheumatic Diseases, 2012, 71, 710-713.	0.9	220
14	B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis. American Journal of Pathology, 2006, 169, 954-966.	3.8	195
15	Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. Journal of Clinical Investigation, 2011, 121, 4268-4280.	8.2	156
16	Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia, 2013, 27, 170-182.	7.2	145
17	Protective and Pathogenic Roles for B Cells during Systemic Autoimmunity in NZB/W F1 Mice. Journal of Immunology, 2010, 184, 4789-4800.	0.8	136
18	Antimelanoma differentiationâ€associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. British Journal of Dermatology, 2017, 176, 395-402.	1.5	131

#	Article	IF	CITATIONS
19	Potential roles of interleukinâ€17A in the development of skin fibrosis in mice. Arthritis and Rheumatism, 2012, 64, 3726-3735.	6.7	118
20	Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?. Journal of Dermatological Science, 2008, 50, 240-242.	1.9	110
21	Inhibitory Role of CD19 in the Progression of Experimental Autoimmune Encephalomyelitis by Regulating Cytokine Response. American Journal of Pathology, 2006, 168, 812-821.	3.8	109
22	The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. British Journal of Dermatology, 2008, 158, 487-495.	1.5	108
23	Identifying Regulatory B Cells (B10 Cells) that Produce IL-10 in Mice. Methods in Molecular Biology, 2010, 677, 99-111.	0.9	106
24	Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. Journal of Rheumatology, 2006, 33, 275-84.	2.0	106
25	BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Science Advances, 2018, 4, eaas9944.	10.3	98
26	Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease. Blood, 2013, 121, 3274-3283.	1.4	92
27	Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology, 2016, 55, 263-267.	1.9	84
28	Regulatory and effector B cells: Friends or foes?. Journal of Dermatological Science, 2019, 93, 2-7.	1.9	84
29	Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps. Neuroscience Letters, 2011, 502, 41-45.	2.1	83
30	Serum chemokine and cytokine levels as indicators of disease activity in patients with systemic sclerosis. Clinical Rheumatology, 2011, 30, 231-237.	2.2	78
31	Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies. PLoS ONE, 2016, 11, e0154746.	2.5	78
32	Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort. Annals of the Rheumatic Diseases, 2013, 72, 151-153.	0.9	77
33	Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clinical and Experimental Immunology, 2004, 138, 357-363.	2.6	76
34	B-cell linker protein expression contributes to controlling allergic and autoimmune diseases by mediating IL-10 production in regulatory B cells. Journal of Allergy and Clinical Immunology, 2013, 131, 1674-1682.e9.	2.9	76
35	Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. British Journal of Rheumatology, 2004, 43, 1261-1266.	2.3	73
36	Primary Cutaneous NK/T-cell Lymphoma, Nasal Type and CD56-positive Peripheral T-cell Lymphoma. American Journal of Surgical Pathology, 2015, 39, 1-12.	3.7	73

#	Article	IF	Citations
37	Clinical and Immunologic Predictors of Scleroderma Renal Crisis in Japanese Systemic Sclerosis Patients With Anti–RNA Polymerase III Autoantibodies. Arthritis and Rheumatology, 2015, 67, 1045-1052.	5.6	70
38	BAFF Antagonist Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Investigative Dermatology, 2007, 127, 2772-2780.	0.7	69
39	The Loss of MCP-1 Attenuates Cutaneous Ischemia–Reperfusion Injury in a Mouse Model of Pressure Ulcer. Journal of Investigative Dermatology, 2008, 128, 1838-1851.	0.7	64
40	Association between nail-fold capillary findings and disease activity in dermatomyositis. Rheumatology, 2011, 50, 1091-1098.	1.9	63
41	Amplified B Lymphocyte CD40 Signaling Drives Regulatory B10 Cell Expansion in Mice. PLoS ONE, 2011, 6, e22464.	2.5	62
42	Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Journal of Rheumatology, 2007, 34, 1012-8.	2.0	62
43	Elevated Serum Insulin-like Growth Factor (IGF-1) and IGF Binding Protein-3 Levels in Patients with Systemic Sclerosis: Possible Role in Development of Fibrosis. Journal of Rheumatology, 2008, 35, 2363-2371.	2.0	60
44	Abnormal Natural Killer Cell Function in Systemic Sclerosis: Altered Cytokine Production and Defective Killing Activity. Journal of Investigative Dermatology, 2005, 125, 731-737.	0.7	55
45	IL-6 Blockade Attenuates the Development of Murine Sclerodermatous Chronic Graft-Versus-Host Disease. Journal of Investigative Dermatology, 2012, 132, 2752-2761.	0.7	55
46	A novel splenic B1 regulatory cell subset suppresses allergic disease through phosphatidylinositol 3-kinase–Akt pathway activation. Journal of Allergy and Clinical Immunology, 2016, 138, 1170-1182.e9.	2.9	54
47	Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Experimental Dermatology, 2007, 16, 87-93.	2.9	53
48	Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. Journal of Dermatological Science, 2005, 40, 215-217.	1.9	51
49	Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Annals of the Rheumatic Diseases, 2008, 67, 867-872.	0.9	50
50	Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. Journal of Rheumatology, 2007, 34, 2056-62.	2.0	50
51	Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis. Journal of Rheumatology, 2011, 38, 877-884.	2.0	47
52	Host-Derived MCP-1 and MIP-1 $\hat{l}$ ± Regulate Protective Anti-Tumor Immunity to Localized and Metastatic B16 Melanoma. American Journal of Pathology, 2012, 180, 365-374.	3.8	47
53	Regulatory B cells and T cell Regulation in Cancer. Journal of Molecular Biology, 2021, 433, 166685.	4.2	43
54	The efficacy of self-administered stretching for finger joint motion in Japanese patients with systemic sclerosis. Journal of Rheumatology, 2006, 33, 1586-92.	2.0	43

#	Article	IF	CITATIONS
55	FTY720 Ameliorates Murine Sclerodermatous Chronic Graftâ€Versusâ€Host Disease by Promoting Expansion of Splenic Regulatory Cells and Inhibiting Immune Cell Infiltration Into Skin. Arthritis and Rheumatism, 2013, 65, 1624-1635.	6.7	40
56	Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. Journal of Leukocyte Biology, 2007, 82, 519-531.	3.3	39
57	A Clue for Telangiectasis in Systemic Sclerosis: Elevated Serum Soluble Endoglin Levels in Patients with the Limited Cutaneous Form of the Disease. Dermatology, 2006, 213, 88-92.	2.1	38
58	Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Annals of the Rheumatic Diseases, 2006, 65, 124-126.	0.9	37
59	Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease. Journal of Dermatological Science, 2014, 74, 214-221.	1.9	37
60	Inducible Costimulator (ICOS) and ICOS Ligand Signaling Has Pivotal Roles in Skin Wound Healing via Cytokine Production. American Journal of Pathology, 2011, 179, 2360-2369.	3.8	36
61	Intercellular Adhesion Molecule-1 Deficiency Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Immunology, 2007, 179, 698-707.	0.8	35
62	Regulation of local and metastatic host-mediated anti-tumour mechanisms by l-selectin and intercellular adhesion molecule-1. Clinical and Experimental Immunology, 2006, 143, 216-227.	2.6	34
63	Early administration of galantamine from preplaque phase suppresses oxidative stress and improves cognitive behavior in APPswe/PS1dE9 mouse model of Alzheimer's disease. Free Radical Biology and Medicine, 2019, 145, 20-32.	2.9	31
64	Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology, 2005, 44, 873-878.	1.9	29
65	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Modern Rheumatology, 2012, 22, 892-898.	1.8	29
66	Transplantation of Mesenchymal Stem Cells Improves Amyloid-Î <sup>2</sup> Pathology by Modifying Microglial Function and Suppressing Oxidative Stress. Journal of Alzheimer's Disease, 2019, 72, 867-884.	2.6	29
67	Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clinical and Experimental Immunology, 2009, 159, 176-184.	2.6	28
68	Dermokine inhibits ELR+CXC chemokine expression and delays early skin wound healing. Journal of Dermatological Science, 2013, 70, 34-41.	1.9	28
69	B Cells Promote Tumor Immunity against B16F10 Melanoma. American Journal of Pathology, 2014, 184, 3120-3129.	3.8	28
70	Comparison of cyclic compression, cyclic distraction and rigid fixation: Bone healing in rabbits. Acta Orthopaedica, 1998, 69, 95-98.	1.4	27
71	Regulatory B cells that produce IL-10: AÂbreath of fresh air in allergic airway disease. Journal of Allergy and Clinical Immunology, 2010, 125, 1125-1127.	2.9	27
72	A Case of Acute Cutaneous Graft-versus-Host Disease Mimicking Psoriasis Vulgaris. Dermatology, 2008, 216, 64-67.	2.1	26

#	Article	IF	CITATIONS
73	Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8+ T Cells. Journal of Investigative Dermatology, 2019, 139, 1535-1544.e1.	0.7	26
74	Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice. Journal of Alzheimer's Disease, 2016, 55, 1235-1247.	2.6	25
75	Severe pneumonitis after nivolumab treatment in a patient with melanoma. Allergology International, 2016, 65, 487-489.	3.3	25
76	Adiposeâ€derived stromal/stem cells successfully attenuate the fibrosis of scleroderma mouse models. International Journal of Rheumatic Diseases, 2020, 23, 216-225.	1.9	25
77	Human Leukocyte Antigen and Systemic Sclerosis in Japanese: The Sign of the Four Independent Protective Alleles, DRB1*13:02, DRB1*14:06, DQB1*03:01, and DPB1*02:01. PLoS ONE, 2016, 11, e0154255.	2.5	25
78	Epstein-Barr virus-associated T-cell lymphoma: a case of eyelid swelling and intramuscular infiltration mimicking dermatomyositis. British Journal of Dermatology, 2002, 147, 1244-1248.	1.5	23
79	Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma. Journal of Dermatological Science, 2021, 101, 174-184.	1.9	22
80	Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis. Experimental Dermatology, 2008, 17, 197-202.	2.9	21
81	Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis. Rheumatology, 2013, 52, 242-251.	1.9	21
82	Blockade of TGF- $\hat{l}^2$ /Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis. Arthritis Research and Therapy, 2018, 20, 46.	3.5	21
83	L-selectin and intercellular adhesion molecule-1 regulate the development of Concanavalin A-induced liver injury. Journal of Leukocyte Biology, 2006, 79, 696-705.	3.3	20
84	CD14 and Toll-Like Receptor 4 Promote Fibrillar A $\hat{1}^2$ 42 Uptake by Microglia Through A Clathrin-Mediated Pathway. Journal of Alzheimer's Disease, 2019, 68, 323-337.	2.6	20
85	Antiâ $\in$ transcriptional intermediary factor $1$ â $\in$ $\hat{\mathfrak{l}}$ 3 antibody as a biomarker in patients with dermatomyositis. Journal of Dermatology, 2020, 47, 64-68.	1.2	20
86	Increased serum soluble CD40 levels in patients with systemic sclerosis. Journal of Rheumatology, 2007, 34, 353-8.	2.0	20
87	Interlocking Intramedullary Nail Method for the Treatment of Femoral and Tibial Fractures in Cats and Small Dogs Journal of Veterinary Medical Science, 1998, 60, 119-122.	0.9	19
88	Lung cancer in connective tissue disease-associated interstitial lung disease: clinical features and impact on outcomes. Journal of Thoracic Disease, 2018, 10, 799-807.	1.4	19
89	Blockade of p38 Mitogen-Activated Protein Kinase Inhibits Murine Sclerodermatous Chronic Graft-versus-Host Disease. American Journal of Pathology, 2017, 187, 841-850.	3.8	18
90	An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics, 2017, 17, 823-833.	3.1	17

#	Article	IF	CITATIONS
91	Elevated serum Bâ $\in$ ell activating factor levels in patients with dermatomyositis: Association with interstitial lung disease. Journal of Dermatology, 2019, 46, 1190-1196.	1.2	17
92	Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 cooperatively contribute to the cutaneous Arthus reaction. Journal of Leukocyte Biology, 2007, 81, 1197-1204.	3.3	16
93	Altered expression of dermokine in skin disorders. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 867-875.	2.4	16
94	A Crucial Role of Lâ€Selectin in C Protein–Induced Experimental Polymyositis in Mice. Arthritis and Rheumatology, 2014, 66, 1864-1871.	5.6	16
95	High prevalence of primary biliary cirrhosis and disease-associated autoantibodies in Japanese patients with systemic sclerosis. Modern Rheumatology, 2012, 22, 892-898.	1.8	16
96	Establishment of Experimental Eosinophilic Vasculitis by IgE-Mediated Cutaneous Reverse Passive Arthus Reaction. American Journal of Pathology, 2009, 174, 2225-2233.	3.8	15
97	Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population. Scientific Reports, 2019, 9, 16366.	3.3	15
98	Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells. Scientific Reports, 2021, 11, 2106.	3.3	15
99	E- and P-Selectins Synergistically Inhibit Bleomycin-Induced Pulmonary Fibrosis. American Journal of Pathology, 2006, 169, 740-749.	3.8	14
100	Sequentially appearing erythema nodosum, erythema multiforme and Henoch-Sch $\tilde{A}$ ¶nlein purpura in a patient with Mycoplasma pneumoniae infection: a case report. Journal of Medical Case Reports, 2012, 6, 398.	0.8	14
101	Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimod. Scientific Reports, 2019, 9, 658.	3.3	13
102	Phase-Dependent Roles of E-Selectin during Chronic Contact Hypersensitivity Responses. American Journal of Pathology, 2007, 170, 1649-1658.	3.8	12
103	A case of aseptic meningitis without neck rigidity occurring in a metastatic melanoma patient treated with ipilimumab. European Journal of Dermatology, 2017, 27, 193-194.	0.6	12
104	Soluble CD163 is a potential biomarker in systemic sclerosis. Expert Review of Molecular Diagnostics, 2019, 19, 197-199.	3.1	12
105	Callus formation in femur and tibia during leg lengthening:7 patients examined with DXA. Acta Orthopaedica, 1996, 67, 158-160.	1.4	11
106	High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies. Modern Rheumatology, 2015, 25, 798-801.	1.8	11
107	Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the <scp>CX</scp> <sub>3</sub> <scp>CR</scp> 1/scp>CX <sub>3</sub> <scp>CR</scp> 1 Pathway in Experimental Mouse Models of Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1923-1934.	5.6	11
108	Regulatory B Cells in Mouse Models of Systemic Lupus Erythematosus (SLE). Methods in Molecular Biology, 2014, 1190, 195-205.	0.9	11

#	Article	IF	CITATIONS
109	Basophils and mast cells play critical roles for leukocyte recruitment in IgE-mediated cutaneous reverse passive Arthus reaction. Journal of Dermatological Science, 2012, 67, 181-189.	1.9	10
110	Anti-topoisomerase I antibody levels as serum markers of skin sclerosis in systemic sclerosis. Journal of Dermatology, 2013, 40, 89-93.	1.2	9
111	Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension. Journal of Dermatological Science, 2009, 55, 66-67.	1.9	8
112	Stevens–Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. Journal of Dermatology, 2019, 46, e434-e436.	1.2	8
113	Evaluation of Mitochondrial Oxidative Stress in the Brain of a Transgenic Mouse Model of Alzheimer's Disease by in vitro Electron Paramagnetic Resonance Spectroscopy. Journal of Alzheimer's Disease, 2019, 67, 1079-1087.	2.6	8
114	CD22 and CD72 contribute to the development of scleroderma in a murine model. Journal of Dermatological Science, 2020, 97, 66-76.	1.9	8
115	SIRT1 decelerates morphological processing of oligodendrocyte cell lines and regulates the expression of cytoskeleton-related oligodendrocyte proteins. Biochemical and Biophysical Research Communications, 2021, 546, 7-14.	2.1	8
116	The diameter of callus in leg lengthening 28 tibial lengthenings in 14 patients with achondroplasia. Acta Orthopaedica, 1998, 69, 306-310.	1.4	7
117	Skin sclerosis as a manifestation of POEMS syndrome. Journal of Dermatology, 2012, 39, 922-926.	1.2	7
118	Longâ€term changes in nail fold capillary abnormalities and serum fibroblast growth factor 23 levels in dermatomyositis patients with antiâ€melanoma differentiating antigen 5 antibody. Journal of Dermatology, 2021, 48, 106-109.	1.2	7
119	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Modern Rheumatology, 2013, 23, 913-919.	1.8	7
120	Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern. Annals of the Rheumatic Diseases, 2022, 81, 742-744.	0.9	7
121	B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting. Expert Review of Neurotherapeutics, 2009, 9, 309-312.	2.8	6
122	Human leukocyte antigen in Japanese patients with idiopathic inflammatory myopathy. Modern Rheumatology, 2020, 30, 696-702.	1.8	6
123	A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor. Immunological Medicine, 2021, 44, 53-55.	2.6	6
124	The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF- $\hat{l}^2$ signaling. Arthritis Research and Therapy, 2022, 24, 94.	3.5	6
125	Childhood Capillary Hemangioma Presenting as Infantile Perianal Protrusion. Dermatology, 2003, 207, 408-409.	2.1	5
126	Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis. Journal of the American Academy of Dermatology, 2010, 62, 142-144.	1,2	5

#	Article	IF	CITATIONS
127	The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Modern Rheumatology, 2014, 24, 377-379.	1.8	5
128	Long-term clinical and radiological improvement of chronic acquired hepatocerebral degeneration after obliteration of portosystemic shunt: Report of a case. Journal of the Neurological Sciences, 2014, 346, 303-306.	0.6	5
129	Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc. Modern Rheumatology, 2017, 27, 614-617.	1.8	5
130	Case of antiâ€transcriptional intermediary factorâ€1â€positive dermatomyositis associated with breast cancer developing over 10 years. Journal of Dermatology, 2017, 44, 972-973.	1.2	5
131	Foodâ€dependent exerciseâ€induced anaphylaxis due to shrimp associated with 43ÂkDa, a new antigen. Journal of Dermatology, 2018, 45, 366-367.	1.2	5
132	Long-term follow-up of finger passive range of motion in Japanese systemic sclerosis patients treated with self-administered stretching. Modern Rheumatology, 2019, 29, 484-490.	1.8	5
133	Availability of EuroQol-5-Dimensions-5-Level (EQ-5D-5L) as health-related QOL assessment for Japanese systemic sclerosis patients. Modern Rheumatology, 2020, 30, 681-686.	1.8	5
134	Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis. Rheumatology, 2020, 59, 3553-3562.	1.9	5
135	Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies. Rheumatology International, 2007, 28, 113-119.	3.0	4
136	Scleroderma: recent lessons from murine models and implications for future therapeutics. Expert Review of Dermatology, 2013, 8, 527-539.	0.3	4
137	Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. Journal of Autoimmunity, 2017, 76, 101-107.	6.5	4
138	Increased interleukinâ€9 levels in sera, muscle and skin of patients with dermatomyositis. Journal of Dermatology, 2018, 45, 1023-1025.	1.2	4
139	Severe Mononeuritis Multiplex due to Rheumatoid Vasculitis in Rheumatoid Arthritis in Sustained Clinical Remission for Decades. Internal Medicine, 2020, 59, 705-710.	0.7	4
140	Clinical features of Japanese systemic sclerosis (SSc) patients negative for SScâ€related autoantibodies: A singleâ€center retrospective study. International Journal of Rheumatic Diseases, 2020, 23, 1219-1225.	1.9	4
141	Clinical association of serum CD137 (4-1BB) levels in patients with systemic sclerosis. Journal of Dermatological Science, 2009, 53, 159-161.	1.9	3
142	The clinical characteristics of juvenile-onset systemic sclerosis in Japanese patients. Modern Rheumatology, $2013, 1.$	1.8	3
143	Clinical and laboratory features dependent on age at onset in Japanese systemic sclerosis. Modern Rheumatology, 2013, 23, 913-919.	1.8	3
144	CD22 and CD72 cooperatively contribute to the development of the reverse Arthus reaction model. Journal of Dermatological Science, 2019, 95, 36-43.	1.9	3

#	Article	IF	CITATIONS
145	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study. Journal of Dermatology, 2020, 47, 1391-1394.	1.2	3
146	Sporadic Amyotrophic Lateral Sclerosis Due to a FUS P525L Mutation with Asymmetric Muscle Weakness and Anti-ganglioside Antibodies. Internal Medicine, 2021, 60, 1949-1953.	0.7	3
147	Case of pembrolizumabâ€induced dermatomyositis with <scp>antiâ€</scp> transcription intermediary factor 1â€Î³ antibody. Journal of Dermatology, 2022, 49, .	1.2	3
148	Cytokineâ€producing Bâ€cell balance associates with skin fibrosis in patients with systemic sclerosis. Journal of Dermatology, 0, , .	1.2	3
149	Two cases of livedo vasculopathy with nonâ€criteria antiphospholipid antibodies. Journal of Dermatology, 2012, 39, 1026-1030.	1.2	2
150	A role for FcγRIIB in the development of murine bleomycin-induced fibrosis. Journal of Dermatological Science, 2021, 104, 201-209.	1.9	2
151	Influence of femoral lengthening on hip joint space in posttraumatic femoral shortening. Acta Orthopaedica, 1997, 68, 541-544.	1.4	1
152	Human case of subcutaneous nodule because of a novel genetic variation of Dirofilaria sp Journal of Dermatology, 2019, 46, 914-916.	1.2	1
153	A case of juvenile localized scleroderma with anti-topoisomerase I antibody. European Journal of Dermatology, 2019, 29, 443-444.	0.6	1
154	Discrepancy in responses to dabrafenib plus trametinib combination therapy in intracranial and extracranial metastases in melanoma patients. Journal of Dermatology, 2021, 48, e82-e83.	1.2	1
155	A case of anti-NXP2 antibody-positive dermatomyositis with improvement of clinical symptoms and disappearance of autoantibody after resection of uterine cancer. European Journal of Dermatology, 2020, 30, 612-613.	0.6	1
156	A crucial role of L-selectin in C protein-induced experimental polymyositis of mice. Journal of Dermatological Science, 2016, 84, e9.	1.9	0
157	The inhibitor of p38 MAP kinase suppresses skin fibrosis in the sclerodermatous chronic GVHD. Journal of Dermatological Science, 2016, 84, e15.	1.9	0
158	Decreased levels of regulatory B cells in patients with systemic sclerosis: Association with autoantibody production and disease activity. Journal of Dermatological Science, 2016, 84, e96.	1.9	0
159	The Role of B Cells in Systemic Sclerosis. , 2016, , 173-185.		0
160	Dual aspects of B cells in tumor immunity; B cells are capable of positive and negative regulation for tumor immunity against B16 melanoma. Journal of Dermatological Science, 2017, 86, e63.	1.9	0
161	A unique CD9 + CD80 + regulatory B cell inhibits contact hypersensitivity response. Journal of Dermatological Science, 2017, 86, e2.	1.9	0
162	Watermelon stomach and colon in a patient with diffuse cutaneous systemic sclerosis. Modern Rheumatology, 2017, 27, 376-377.	1.8	0

#	Article	IF	CITATIONS
163	A case of dermatomyositis with the antiâ€signal recognition particle antibody that was successfully treated with prednisolone and intravenous immunoglobulin therapy. Journal of Dermatology, 2019, 46, e251-e253.	1.2	0
164	Augmented interferon I signaling in a patient with COVID toes. Journal of Dermatology, 2021, 48, e242-e243.	1.2	0
165	B Cell Role in the Pathogenesis of Systemic Sclerosis. Nishinihon Journal of Dermatology, 2021, 83, 397-401.	0.0	O
166	The Hand and Environment (4). Journal of UOEH, 1982, 4, 33-40.	0.6	0
167	A case of Merkel cell carcinoma of the right big toe with Merkel cell polyomavirus infection. Skin Cancer, 2016, 31, 30-34.	0.0	O
168	A case of myxofibrosarcoma with lung metastasis. Skin Cancer, 2016, 31, 35-39.	0.0	0
169	Successful radiation therapy for primary cutaneous follicle center lymphoma. Journal of Case Reports in Medicine, 2019, 8, .	0.0	O
170	A case of antiâ€OJ antibodyâ€positive polymyositis with marked muscle involvement and interstitial lung disease. Journal of Cutaneous Immunology and Allergy, 2021, 4, 13-16.	0.3	0
171	A case of anti-NXP2 antibody-positive dermatomyositis with improvement of clinical symptoms and disappearance of autoantibody after resection of uterine cancer. European Journal of Dermatology, 2020, 30, 612-613.	0.6	0
172	A case of lymphoma-associated haemophagocytic syndrome in advanced-stage mycosis fungoides. European Journal of Dermatology, 2020, 30, 606-608.	0.6	0
173	Increased expression levels of $Fc\hat{l}^3RIIB$ on $na\tilde{A}$ ve and double-negative memory B cells in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 23-31.	0.8	О